This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/07/2023 12:30

BUY CESC

Profitability increase - A key positive

Power > Result Update > August 6, 2023

CESC reported Q1FY24 PAT growth of 23% YoY, both at the standalone and consolidated levels. At the standalone level, power demand growth of 7.5%, T&D loss at 7.5% (vs. 9% as allowed) along with high PLF (over 93%) helped in achieving this growth. Merchant prices helped in improving profitability of Dhariwal Infra (Rs790mn vs. Rs710mn) and Crescent Power (Rs200mn vs. Rs40mn), while Noida continued with increased profitability trend. More importantly, all three Rajasthan DFs have turned positive and reported combined PAT of Rs170mn during the quarter vs. Rs60mn YoY. Over the next few years, improvement in standalone PAT, lower loss levels at DFs, and higher PAT at Noida will all lead to improved consolidated earnings. On account of improving operational and financial metrics, we believe the worst has been factored in and, hence, reiterate our BUY rating, with a Jun-24E TP of Rs100/share. Our bear case value stands at Rs74/share.

CESC: Financial Sna	CESC: Financial Snapshot (Consolidated)						
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E		
Revenue	1,25,439	1,42,460	1,38,944	1,44,386	1,50,453		
EBITDA	36,538	34,250	37,450	38,072	39,303		
Adj. PAT	13,581	13,430	14,947	15,666	17,002		
Adj. EPS (Rs)	10.2	10.1	11.2	11.8	12.8		
EBITDA margin (%)	29.1	24.0	27.0	26.4	26.1		
EBITDA growth (%)	1.8	(6.3)	9.3	1.7	3.2		
Adj. EPS growth (%)	2.0	(1.1)	11.3	4.8	8.5		
RoE (%)	13.4	12.6	13.2	12.9	13.0		
RoIC (%)	7.8	7.8	8.2	8.4	8.9		
P/E (x)	7.7	7.8	7.0	6.7	6.2		
EV/EBITDA (x)	5.9	6.4	5.7	5.2	4.8		
P/B (x)	1.0	1.0	0.9	0.8	0.8		
FCFF yield (%)	11.4	5.1	10.3	15.8	11.9		
Courses Company Embors	Decearch						

Source: Company, Emkay Research

Strong earnings growth on standalone level

CESC reported standalone PAT of Rs1.7bn – 23% YoY growth on account of 7.5% YoY volume growth. Tariff largely remained nearly constant in the Kolkata license area and, hence, higher volume led to improvement. T&D loss in the circle stood at ~7.5%, as against 9% as per the terms and conditions of the tariff, which would have increased profitability. Budge budge reported PLF of 93.5% in Q1FY24 vs. 89.3% YoY.

Subsidiary performance also sees improvement

Consolidated PAT for the quarter stood at Rs3.68bn vs. Rs2.97bn YoY. Standalone/Noida Power/Crescent Power/Dhariwal Infra all showed improvement in PAT. Noida Power reported PAT of Rs540mn vs. Rs340mn, while Crescent Power reported PAT of Rs200mn (Rs40mn in QF1Y23) because of good merchant prices. Rajasthan DFs reported positive bottom-line across all three circles, with further reduction in T&D loss. Combined PAT for the three circles stood at Rs170mn vs. Rs60mn YoY. Management remains confident of positive PAT for these circles during FY24 (FY23 reported loss of Rs250mn). PLF at Haldia/ Chandrapur stood at 93.9%/90.4% as against 89.1%/86.3% during Q1FY24. The company also signed a long-term renewable PPA to procure 150MW Wind-Solar hybrid for a duration of 25 years. UPERC issued the FY24 tariff order for Noida power.

Valuation and outlook

CESC has underperformed a majority of the utilities in the past two years owing to no increase in tariff in Kolkata license area and not much improvement in distribution circles in Rajasthan (these have been reporting loss for the past few years). We believe the company's current profitability has shown signs of improvement on both these assets. Further, profitability of Dhariwal and Noida Power has seen an uptick and will lead to better consolidated PAT going ahead. We reiterate our BUY rating on the stock, with Jun-24 TP of Rs100/share.



Ticker

TARGET PRICE (Rs): 100

Target Price – 12M	Jun-24
Change in TP (%)	5.1
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	26.7
CMP (04-Aug-23) (Rs)	78.8

Stock Data

52-week High (Rs)	87
52-week Low (Rs)	62
Shares outstanding (mn)	1,325.6
Market-cap (Rs bn)	104
Market-cap (USD mn)	1,261
Net-debt, FY24E (Rs mn)	1,07,487
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	243.8
ADTV-3M (USD mn)	2.9
Free float (%)	-
Nifty-50	19,517
INR/USD	82.8
Shareholding, Jun-23	
Promoters (%)	52.1
FPIs/MFs (%)	12.2/21.0

Price Performance						
(%)	1M	3M	12M			
Absolute	8.0	14.0	(1.4)			
Rel. to Nifty	7.3	6.6	(12.2)			



Abhineet Anand


abhineet.anand@emkayglobal.com +91 22 6624 2466

Eshan Bhargava Eshan.bhargava@emkayglobal.com +91 22 6624 2453

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Revenue increased significantly but EBITDAM declined




Source: Company, Emkay Research

Exhibit 3: Revenue increased across units, barring the leading two




Source: Company, Emkay Research


Exhibit 5: The power sales mix was in favor of purchased power





Source: Company, Emkay Research

Exhibit 2: T&D losses declined by 66bps YoY










Source: Company, Emkay Research

Exhibit 6: ROE and ROCE expected to remain flat





This report is intended for team.emkay@whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM. Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: Standalone Quarterly Results

	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	YoY (%)	QoQ (%)
Revenues	23,470	22,630	17,080	16,550	25,250	8%	53%
Fuel Cost	14,990	14,200	9,790	9,060	16,460	10%	82%
as % of sales	63.9	62.7	57.3	54.7	65.2	132 bps	1044 bps
Employee Cost	2,310	2,760	2,380	2,380	2,570	11%	8%
as % of sales	9.8	12.2	13.9	14.4	10.2	34 bps	-420 bps
Other expenditure	2,230	2,470	2,660	2,730	2,780	25%	2%
as % of sales	9.5	10.9	15.6	16.5	11.0	151 bps	-549 bps
Total expenditure	19,530	19,430	14,830	14,170	21,810	12%	54%
EBITDA	3,940	3,200	2,250	2,380	3,440	-13%	45%
Depreciation	1,200	1,190	1,190	1,220	1,790	49%	47%
EBIT	2,740	2,010	1,060	1,160	1,650	-40%	42%
Other Income	200	480	560	560	210	5%	-63%
Interest	1,340	1,480	1,560	1,660	1,810	35%	9%
РВТ	1,600	1,010	60	60	50	-97%	-17%
Taxes	350	680	510	760	450	29%	-41%
Regulatory Income	130	2,100	2,310	3,330	2,100	1515%	-37%
PAT	1,380	2,430	1,860	2,630	1,700	23%	-35%
Share in JV/ Associates	0	0	0	0	0		
Minority interest	0	0	0	0	0		
Adjusted PAT	1,380	2,430	1,860	2,630	1,700	23%	-35%
Adjusted EPS	1.04	1.82	1.40	1.97	1.28	23%	-35%
Margins (%)							
Gross Margins	36.1	37.3	42.7	45.3	34.8	-132 bps	-1044 bps
EBIDTAM	16.8	14.1	13.2	14.4	13.6	-316 bps	-76 bps
EBITM	11.7	8.9	6.2	7.0	6.5	-514 bps	-47 bps
РВТМ	6.8	4.5	0.4	0.4	0.2	-662 bps	-16 bps
PATM	5.9	10.7	10.9	15.9	6.7	85 bps	-916 bps
Effective Tax rate	21.9	67.3	850.0	1,266.7	900.0	N.A.	N.A.

Source: Company, Emkay Research

Exhibit 8: SoTP – June-24

	Value (Rs mn)	Multiple	Method	Stake	Target Value (Rs mn)	Rs/share	Bear case (Rs/share)	Remarks
Distribution					· · ·			
Kolkata Reg Equity	37,074	~1.5	(RoE-g)/(CoE-g)	100%	55,699	42	38	1.4x for Bear case
Noida	6,928	2.1	(RoE-g)/(CoE-g)	73.0%	10,647	8	7	1.4x for Bear case
Distribution Franchisee	4,115	1.5	Equity Investment	100.0%	6,173	5	-3	On improvement
Chandigarh License	1,800	1.5	Equity Investment	100.0%				On handover
Total					72,519	54	42	
Generation								
Kolkata Reg Equity	12,848	1.4	RoE/Ke	100%	17,876	13	13	1.35x for Bear case
Haldia Reg Equity	10,500	2.0	RoE/Ke	100%	21,000	16	11	1.35x for Bear case
Dhariwal/Chandrapur	14,962	1.0	NPV	100%	14,962	11	4	
Total					53,838	40	27	
Dividend per share					5,995	5	5	
SoTP – Jun-24					1,32,352	100	74	

Source: Company

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

CESC: Consolidated Financials and Valuations

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	1,25,439	1,42,460	1,38,944	1,44,386	1,50,453
Revenue growth (%)	7.8	13.6	(2.5)	3.9	4.2
EBITDA	36,538	34,250	37,450	38,072	39,303
EBITDA growth (%)	1.8	(6.3)	9.3	1.7	3.2
Depreciation & Amortization	8,847	8,780	9,166	9,338	9,378
EBIT	27,691	25,470	28,284	28,734	29,925
EBIT growth (%)	1.7	(8.0)	11.0	1.6	4.1
Other operating income	0	0	0	0	0
Other income	2,757	3,090	3,214	3,342	3,476
Financial expense	11,293	11,170	11,626	11,231	10,786
РВТ	19,155	17,390	19,872	20,845	22,615
Extraordinary items	0	0	0	0	0
Taxes	5,114	3,420	4,372	4,586	4,975
Minority interest	460	540	553	593	637
Income from JV/Associates	0	0	0	0	0
Reported PAT	13,581	13,430	14,947	15,666	17,002
PAT growth (%)	2.0	(1.1)	11.3	4.8	8.5
Adjusted PAT	13,581	13,430	14,947	15,666	17,002
Diluted EPS (Rs)	10.2	10.1	11.2	11.8	12.8
Diluted EPS growth (%)	2.0	(1.1)	11.3	4.8	8.5
DPS (Rs)	4.5	4.5	4.9	5.3	5.6
Dividend payout (%)	44.4	45.0	43.3	44.9	43.6
EBITDA margin (%)	29.1	24.0	27.0	26.4	26.1
EBIT margin (%)	22.1	17.9	20.4	19.9	19.9
Effective tax rate (%)	26.7	19.7	22.0	22.0	22.0
NOPLAT (pre-IndAS)	20,298	20,461	22,062	22,412	23,341
Shares outstanding (mn)	1,332.2	1,332.0	1,332.0	1,332.0	1,332.0

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	1,332	1,332	1,332	1,332	1,332
Reserves & Surplus	1,02,632	1,07,770	1,16,250	1,24,886	1,34,480
Net worth	1,03,964	1,09,102	1,17,582	1,26,218	1,35,812
Minority interests	4,342	4,790	5,343	5,936	6,574
Deferred tax liability (net)	42,875	42,790	42,790	42,790	42,790
Total debt	1,47,389	1,40,620	1,37,902	1,37,902	1,35,069
Total liabilities & equity	2,98,570	2,97,302	3,03,617	3,12,846	3,20,245
Net tangible fixed assets	2,30,187	2,26,340	2,25,494	2,22,107	2,20,884
Net intangible assets	1,340	1,290	1,290	1,290	1,290
Net ROU assets	6,755	6,755	6,755	6,755	6,755
Capital WIP	1,025	1,400	1,400	1,400	1,400
Goodwill	0	0	0	0	0
Investments [JV/Associates]	1,774	1,400	1,400	1,400	1,400
Cash & equivalents	35,946	25,880	30,415	46,521	51,060
Current assets (ex-cash)	84,319	1,01,060	1,00,870	1,02,065	1,03,363
Current Liab. & Prov.	56,021	60,068	57,252	61,937	59,152
NWC (ex-cash)	28,298	40,992	43,618	40,128	44,211
Total assets	2,98,570	2,97,302	3,03,617	3,12,846	3,20,246
Net debt	1,11,443	1,14,740	1,07,487	91,381	84,009
Capital employed	2,98,570	2,97,302	3,03,617	3,12,846	3,20,245
Invested capital	2,58,485	2,67,332	2,69,112	2,62,235	2,65,096
BVPS (Rs)	78.0	81.9	88.3	94.8	102.0
Net Debt/Equity (x)	1.1	1.1	0.9	0.7	0.6
Net Debt/EBITDA (x)	3.1	3.4	2.9	2.4	2.1
Interest coverage (x)	0.4	0.4	0.4	0.4	0.3
RoCE (%)	10.4	9.6	10.5	10.4	10.6

Source: Company, Emkay Research

Balance Sheet

Cash Flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	19,155	17,390	19,872	20,845	22,615
Others (non-cash items)	0	0	0	0	C
Taxes paid	(3,917)	(2,980)	(2,461)	(2,461)	(2,461)
Change in NWC	(7,290)	(12,779)	(2,626)	3,490	(4,083)
Operating cash flow	23,766	16,509	30,199	36,937	30,594
Capital expenditure	986	(5,308)	(8,320)	(5,951)	(8,155)
Acquisition of business	249	374	0	0	(
Interest & dividend income	991	991	991	991	991
Investing cash flow	2,231	1,607	(5,106)	(2,609)	(4,679)
Equity raised/(repaid)	0	0	0	0	(
Debt raised/(repaid)	6,974	(6,769)	(2,718)	0	(2,833
Payment of lease liabilities	(471)	(460)	(460)	(460)	(460)
Interest paid	(11,293)	(11,170)	(11,626)	(11,231)	(10,786
Dividend paid (incl tax)	(6,026)	(6,040)	(6,467)	(7,031)	(7,407
Others	(1,736)	(752)	253	40	(350
Financing cash flow	(12,082)	(24,731)	(20,558)	(18,222)	(21,376)
Net chg in Cash	13,915	(6,615)	4,535	16,106	4,539
OCF	23,766	16,509	30,199	36,937	30,594
Adj. OCF (w/o NWC chg.)	16,476	3,730	27,573	40,427	26,511
FCFF	24,753	11,201	21,879	30,986	22,439
FCFE	14,451	1,022	11,245	20,746	12,644
OCF/EBITDA (%)	65.0	48.2	80.6	97.0	77.8
FCFE/PAT (%)	106.4	7.6	75.2	132.4	74.4
FCFF/NOPLAT (%)	121.9	54.7	99.2	138.3	96.1

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and Key Ra	tios				
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	7.7	7.8	7.0	6.7	6.2
P/CE(x)	4.7	4.7	4.4	4.2	4.0
P/B (x)	1.0	1.0	0.9	0.8	0.8
EV/Sales (x)	1.7	1.5	1.5	1.4	1.3
EV/EBITDA (x)	5.9	6.4	5.7	5.2	4.8
EV/EBIT(x)	7.8	8.6	7.5	6.8	6.3
EV/IC (x)	0.8	0.8	0.8	0.7	0.7
FCFF yield (%)	11.4	5.1	10.3	15.8	11.9
FCFE yield (%)	13.8	1.0	10.7	19.8	12.0
Dividend yield (%)	5.7	5.8	6.2	6.7	7.1
DuPont-RoE split					
Net profit margin (%)	10.8	9.4	10.8	10.9	11.3
Total asset turnover (x)	0.4	0.5	0.5	0.5	0.5
Assets/Equity (x)	2.9	2.8	2.7	2.5	2.4
RoE (%)	13.4	12.6	13.2	12.9	13.0
DuPont-RoIC					
NOPLAT margin (%)	16.2	14.4	15.9	15.5	15.5
IC turnover (x)	0.0	0.0	0.0	0.0	0.0
RoIC (%)	7.8	7.8	8.2	8.4	8.9
Operating metrics					
Core NWC days	82.3	105.0	114.6	101.4	107.3
Total NWC days	82.3	105.0	114.6	101.4	107.3
Fixed asset turnover	0.4	0.5	0.4	0.5	0.5
Opex-to-revenue (%)	42.6	39.6	41.5	41.4	41.2

Source: Company, Emkay Research

This report is intended for team emkay @ whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY GOD. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	CMP (INR)	TP (INR)	Rating	Analyst
23-May-23	70	95	Buy	Abhineet Anand
15-May-23	71	95	Buy	Abhineet Anand
06-Mar-23	70	101	Buy	Abhineet Anand
15-Feb-23	77	101	Buy	Abhineet Anand
05-Feb-23	73	101	Buy	Abhineet Anand
04-Jan-23	77	101	Buy	Abhineet Anand
06-Dec-22	75	101	Buy	Abhineet Anand
15-Nov-22	75	101	Buy	Abhineet Anand
26-Sep-22	78	108	Buy	Abhineet Anand
11-Sep-22	83	108	Buy	Abhineet Anand
21-Jun-22	71	108	Buy	Abhineet Anand
09-Jun-22	78	108	Buy	Abhineet Anand
15-May-22	79	108	Buy	Abhineet Anand
22-Feb-22	76	101	Buy	Abhineet Anand
13-Jan-22	92	101	Buy	Abhineet Anand
22-Nov-21	84	101	Buy	Abhineet Anand
14-Jul-21	85	98	Buy	Abhineet Anand

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of August 6, 2023
- GFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of August 6, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the August 6, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.